"Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.
暂无分享,去创建一个
Fernando Alarid-Escudero | Hawre Jalal | Eva A Enns | Karen M Kuntz | Tzeyu L Michaud | K. Kuntz | Tzeyu L. Michaud | E. Enns | F. Alarid-Escudero | Hawre J. Jalal | Hawre Jalal
[1] Jonathan Karnon,et al. Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .
[2] Jonathan Karnon,et al. Model Parameter Estimation and Uncertainty Analysis , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[3] Gordon B. Hazen,et al. A Bayesian approach to sensitivity analysis. , 1999, Health economics.
[4] Simon Eckermann,et al. The Value of Value of Information , 2012, PharmacoEconomics.
[5] Bas Groot Koerkamp,et al. Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[6] Mark Strong,et al. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment , 2017, PharmacoEconomics.
[7] Gordon B. Hazen,et al. Sensitivity Analysis and the Expected Value of Perfect Information , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[8] Joshua T. Cohen,et al. The Adoption of Cost-Effectiveness Acceptability Curves in Cost-Utility Analyses , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.
[9] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[10] M. Sculpher,et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.
[11] A A Stinnett,et al. Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[12] M. Sculpher,et al. Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.
[13] J. McCarten,et al. Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis , 2017, PharmacoEconomics - Open.
[14] Andrew Briggs,et al. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.
[15] Andrew Briggs,et al. Health Technology Assessment in the Cost-Disutility Plane , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[16] Simon Eckermann,et al. Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies , 2011, PharmacoEconomics.
[17] D. Currow,et al. Better Informing Decision Making with Multiple Outcomes Cost-Effectiveness Analysis under Uncertainty in Cost-Disutility Space , 2015, PloS one.
[18] Fernando Alarid-Escudero,et al. An Overview of R in Health Decision Sciences , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.
[19] Elisabeth Fenwick,et al. A guide to cost-effectiveness acceptability curves. , 2005, The British journal of psychiatry : the journal of mental science.
[20] M. Sculpher,et al. Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[21] H. Raiffa,et al. Applied Statistical Decision Theory. , 1961 .
[22] Karl Claxton,et al. Exploring Uncertainty in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.
[23] E. Heintz,et al. Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries , 2015, PharmacoEconomics.
[24] Mark Oppe,et al. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] M. Sculpher,et al. Reflecting Uncertainty in Cost-Effectiveness Analysis , 2016 .
[26] Andrew H Briggs,et al. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[27] K Claxton,et al. An economic approach to clinical trial design and research priority-setting. , 1996, Health economics.